Rinvoq Solution
Product Images NDC 0074-2320

27 FDA label images from Abbvie Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 27 technical images submitted to the FDA as part of the official labeling for Rinvoq (NDC 0074-2320). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Upadacitinib-chem-structure (Rinvoq 01)

Upadacitinib-chem-structure (Rinvoq 01)
Chemical structure diagram of Upadacitinib, the active ingredient in Rinvoq. The diagram shows the molecular framework including specific ring systems and functional groups characteristic of Upadacitinib.*
FDA Label Image

Figure 1. Percent Of Patients Achieving Acr20 In Trial Ra-iv (Rinvoq 02)

Figure 1. Percent Of Patients Achieving Acr20 In Trial Ra-iv (Rinvoq 02)
A line graph comparing the percent of responders over 14 weeks between two groups: Rinvoq 15 mg with methotrexate (MTX) and placebo with MTX. The X-axis represents weeks, and the Y-axis represents percent responders, showing higher and increasing response rates for Rinvoq + MTX compared to placebo + MTX.*
FDA Label Image

Figure 2. Percent Of Patients Achieving Acr20 In Study Psa-ii (Rinvoq 03)

Figure 2. Percent Of Patients Achieving Acr20 In Study Psa-ii (Rinvoq 03)
A line graph comparing the percent responders over 12 weeks between Rinvoq 15 mg and placebo groups. The y-axis shows percent responders, and the x-axis shows time in weeks. The Rinvoq group shows a higher and steadily increasing response compared to the placebo group, which remains lower and plateaus around week 8.*
FDA Label Image

Figure 3: Proportion Of Patients With Moderate To Severe Ad With ≥4-point Improvement In The Worst Pruritus Nrs In Monotherapy Trials (Rinvoq 04)

Figure 3: Proportion Of Patients With Moderate To Severe Ad With ≥4-point Improvement In The Worst Pruritus Nrs In Monotherapy Trials (Rinvoq 04)
A dual-panel line graph comparing response rates over 16 weeks in two clinical trials (Trial AD-1 and Trial AD-2) for Rinvoq extended-release tablets at 15 mg and 30 mg dosages daily versus placebo. The y-axis shows response rate percentage, and the x-axis shows time in weeks, illustrating increases over time for both Rinvoq doses compared to placebo.*
FDA Label Image

Figure 4: Proportion Of Patients With Moderate To Severe Ad With ≥4-point Improvement In The Worst Pruritus Nrs In Concomitant Tcs Trial (Rinvoq 05)

Figure 4: Proportion Of Patients With Moderate To Severe Ad With ≥4-point Improvement In The Worst Pruritus Nrs In Concomitant Tcs Trial (Rinvoq 05)
A line graph showing response rates (%) over 16 weeks for three groups: Placebo + TCS, Rinvoq 15 mg QD + TCS, and Rinvoq 30 mg QD + TCS. Both Rinvoq doses show higher and stable response rates after week 4 compared to placebo, with Rinvoq 30 mg having the highest response rate.*
FDA Label Image

Figure 5. Percent Of Patients Achieving Asas40 In Trial As-ii* (Rinvoq 06)

Figure 5. Percent Of Patients Achieving Asas40 In Trial As-ii* (Rinvoq 06)
A line graph depicting percent responders over a period of 14 weeks for Rinvoq 15 mg compared to placebo. The X-axis represents weeks, and the Y-axis shows percent responders, with Rinvoq demonstrating a higher response rate than placebo throughout the study duration.*
FDA Label Image

Figure 6. Percent Of Patients Achieving Asas40* (Rinvoq 07)

Figure 6. Percent Of Patients Achieving Asas40* (Rinvoq 07)
Packaging label for Rinvoq 15 mg extended-release oral tablets by AbbVie Inc. The carton contains 30 tablets with instructions to dispense in original packaging. The label includes directions for opening and puncturing foil, a barcode, and contact information for Rinvoq customer support.*
FDA Label Image

Icondescription Automatically Generated (Rinvoq 08)

Icondescription Automatically Generated (Rinvoq 08)
Rinvoq 15 mg extended-release tablets packaging label by AbbVie Inc. The label indicates it contains 14 tablets and is marked as a professional sample not for sale. The packaging includes instructions to dispense in the original packaging, with a visual of a tablet and a foil cutting tool infographic labeled for puncturing instructions. The label also shows the NDC number 0074-2306-70 and states the product is for oral use.*
FDA Label Image

A Diagram Of A Syringe And A Bottledescription Automatically Generated (Rinvoq 09)

A Diagram Of A Syringe And A Bottledescription Automatically Generated (Rinvoq 09)
Rinvoq 30 mg extended-release tablets packaging label for oral use. The label features the brand and generic name Upadacitinib, with dosage strength prominently displayed. It includes usage instructions, a foil cutting tool guide, and contact information for customer support. The labeler is AbbVie Inc., and the package contains 30 tablets in the original dispensing container.*
FDA Label Image

A Black And White Illustration Of A Bottledescription Automatically Generated (Rinvoq 0a)

A Black And White Illustration Of A Bottledescription Automatically Generated (Rinvoq 0a)
Rinvoq 30 mg extended-release oral tablets packaging label from AbbVie Inc. The label indicates it is a professional sample not for sale and includes dosing instructions. The box design displays the product name, upadacitinib as the active ingredient, a dosage strength of 30 mg, 14 tablets count, and storage instructions. Additional information includes a foil cutting tool illustration and contact information for customer support.*
FDA Label Image

A Syringe And Eyedescription Automatically Generated (Rinvoq 0b)

A Syringe And Eyedescription Automatically Generated (Rinvoq 0b)
Rinvoq 45 mg extended-release tablets packaging label, featuring the product name, Upadacitinib as the active ingredient, and dosage strength of 45 mg. The label includes dosing instructions, a barcode, and contact information for AbbVie Inc., the labeler. The carton design indicates 28 tablets per package and shows instructions for puncturing foil and dispensing with a medication guide.*
FDA Label Image

A Close-up Of A Hand Holding A Bottledescription Automatically Generated (Rinvoq 0c)

A Close-up Of A Hand Holding A Bottledescription Automatically Generated (Rinvoq 0c)
Packaging label for Rinvoq 45 mg extended-release tablets by AbbVie Inc. The label shows the product name Rinvoq with the active ingredient Upadacitinib, specifying 45 mg strength and oral extended-release tablet form. It includes instructions to dispense in the original packaging with the enclosed medication guide, a professional sample notice, and directions for opening with a foil cutting tool. The label also features the NDC number, barcode, and the AbbVie logo.*
FDA Label Image

A Close-up Of A Bottledescription Automatically Generated (Rinvoq 0d)

A Close-up Of A Bottledescription Automatically Generated (Rinvoq 0d)
An instructional illustration showing a finger pressing down on a bottle cap and indicating to twist the cap off in a counterclockwise direction. The image highlights the mechanism of opening a child-resistant or safety cap commonly used on medication bottles.*
FDA Label Image

A Hand Holding A Bottle And A Dropperdescription Automatically Generated (Rinvoq 0e)

A Hand Holding A Bottle And A Dropperdescription Automatically Generated (Rinvoq 0e)
An instructional illustration showing two steps for using a medication bottle with a dropper or dispenser. The first step depicts pressing down on a lever or pump attached to the bottle with a downward arrow. The second step shows dispensing the liquid into a small cup or hand, indicated by a downward arrow and a clockwise curved arrow above the bottle.*
FDA Label Image

A Picture Containing Shapedescription Automatically Generated (Rinvoq 0f)

A Picture Containing Shapedescription Automatically Generated (Rinvoq 0f)
An instructional diagram demonstrating the proper technique to draw liquid medication into a syringe. It shows a hand holding a vial upside down and pulling back the syringe plunger. A detailed inset advises avoiding air bubbles, showing a comparison of syringes with and without air bubbles near the needle. An eye icon indicates careful visual inspection is needed.*
FDA Label Image

Diagramdescription Automatically Generated (Rinvoq 10)

Diagramdescription Automatically Generated (Rinvoq 10)
An instructional illustration showing a hand holding an injector device, demonstrating how to withdraw liquid medicine into a syringe by moving the syringe plunger up and down.*
FDA Label Image

A Picture Containing Diagramdescription Automatically Generated (Rinvoq 11)

A Picture Containing Diagramdescription Automatically Generated (Rinvoq 11)
An instructional illustration showing a hand holding a vial upside down with the other hand drawing liquid into a syringe. A magnified inset displays the syringe's plunger position and fluid level, emphasizing proper technique for drawing medication.*
FDA Label Image

Diagramdescription Automatically Generated (Rinvoq 12)

Diagramdescription Automatically Generated (Rinvoq 12)
Instructional diagram showing the steps to withdraw liquid medicine from a bottle using a syringe. The image depicts a hand holding a bottle upside down, with an arrow indicating insertion of the syringe into the bottle and drawing up the liquid.*
FDA Label Image

Diagramdescription Automatically Generated (Rinvoq 13)

Diagramdescription Automatically Generated (Rinvoq 13)
An instructional illustration showing an eye looking at a syringe, with a check mark next to the syringe, suggesting correct visual verification of the syringe before use.*
FDA Label Image

A Close-up Of A Stethoscopedescription Automatically Generated With Medium Confidence (Rinvoq 14)

A Close-up Of A Stethoscopedescription Automatically Generated With Medium Confidence (Rinvoq 14)
An instructional illustration showing a person administering an oral dose using a syringe-like device aimed at the mouth. The image highlights proper positioning of the hand and device for oral delivery, relevant for liquid medications such as Rinvoq oral solution.*
FDA Label Image

A Picture Containing Vector Graphics, Linedrawingdescription Automatically Generated (Rinvoq 15)

A Picture Containing Vector Graphics, Linedrawingdescription Automatically Generated (Rinvoq 15)
Instructional illustration showing how to open a medication bottle with a child-resistant cap and how to place the bottle into a carton box. The two-step diagram depicts twisting the cap to open the bottle on the left and inserting the bottle into a box on the right.*
FDA Label Image

Diagramdescription Automatically Generated (Rinvoq 16)

Diagramdescription Automatically Generated (Rinvoq 16)
An instructional illustration showing two hands preparing a syringe by filling it with liquid under running faucet water. One hand holds the syringe vertically, while the other hand holds an attached plunger-like component, demonstrating a preparation step likely related to medication administration or dilution.*
FDA Label Image

Arrow (Rinvoq 17)

FDA Label Image

Ndc 0074-2306-30 Rinvoq®upadacitinib Extended-release Tablets 15 mgrinvoq And Rinvoq Lqare Not Substitutabledispense In Original Packaging Flip Cap To Cut Foil Peel Back For Instructions 30 Tablets Rx Only Abbvie (Rinvoq 18)

Ndc 0074-2306-30 Rinvoq®upadacitinib Extended-release Tablets 15 mgrinvoq And Rinvoq Lqare Not Substitutabledispense In Original Packaging Flip Cap To Cut Foil Peel Back For Instructions 30 Tablets Rx Only Abbvie (Rinvoq 18)
Rinvoq 15 mg extended-release oral tablets packaging label featuring the brand and generic name Upadacitinib. The label indicates the tablets are extended-release, comes in a blister pack of 30 tablets, with specific instructions to flip the cap to cut foil and peel back for instructions. The label also notes Rinvoq and Rinvoq LQ are not substitutable. The labeler is AbbVie Inc.*
FDA Label Image

Ndc 0074-2310-30 Rinvoq®upadacitinib Extended-release Tablets30 mgrinvoq And Rinvoq Lqare Not Substitutabledispense In Original Packaging Flip Cap To Cut Foil Peel Back For Instructions 30 Tablets Rx Only Abbvie (Rinvoq 19)

Ndc 0074-2310-30 Rinvoq®upadacitinib Extended-release Tablets30 mgrinvoq And Rinvoq Lqare Not Substitutabledispense In Original Packaging Flip Cap To Cut Foil Peel Back For Instructions 30 Tablets Rx Only Abbvie (Rinvoq 19)
Rinvoq 30 mg extended-release tablets label from AbbVie Inc. The image shows tablet packaging instructions, including a flip cap to cut foil for dispensing 30 tablets. It notes that Rinvoq and Rinvoq LQ are not substitutable and is marked Rx only.*
FDA Label Image

Principal Display Panelndc 0074-1043-28 Rinvoq®upadacitinib Extended-release Tablets45 mgrinvoq And Rinvoq Lqare Not Substitutabledispense With Medication Guide Flip Cap To Cut Foil Peel Back For Instructions 28 Tablets Rx Only Abbvie (Rinvoq 1a)

Principal Display Panelndc 0074-1043-28 Rinvoq®upadacitinib Extended-release Tablets45 mgrinvoq And Rinvoq Lqare Not Substitutabledispense With Medication Guide Flip Cap To Cut Foil Peel Back For Instructions 28 Tablets Rx Only Abbvie (Rinvoq 1a)
Rinvoq 45 mg extended-release tablets packaging label by AbbVie Inc. The label indicates the product name Rinvoq with the active ingredient upadacitinib. It specifies the tablet strength as 45 mg and a quantity of 28 tablets. Instructions include flipping the cap to cut foil and peeling back for directions, with a note that Rinvoq and Rinvoq LQ are not substitutable.*
FDA Label Image

Principal Display Panelndc 0074-2320-01 Rinvoq®lqupadacitiniboral Solution1 mg/mlrinvoq Lq And Rinvoqare Not Substitutable.insert Bottle Adapteron First Use.do Not Removeafter Insertion.180 mL Per Bottlerx Onlyabbvie (Rinvoq 1b)

Principal Display Panelndc 0074-2320-01 Rinvoq®lqupadacitiniboral Solution1 mg/mlrinvoq Lq And Rinvoqare Not Substitutable.insert Bottle Adapteron First Use.do Not Removeafter Insertion.180 mL Per Bottlerx Onlyabbvie (Rinvoq 1b)
Rinvoq LQ 1 mg/mL oral solution carton label for upadacitinib by AbbVie Inc. The label indicates 180 mL per bottle with a reusable oral syringe and adapter included. The packaging notes prescription use, storage instructions (36°F to 86°F, avoid light and freezing), and advises discarding contents 60 days after first opening. The label states Rinvoq LQ and Rinvoq are not substitutable.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.